Background
==========

Inflammatory bowel diseases (IBDs) are a group of chronic and nonspecific inflammatory diseases that mainly comprise ulcerative colitis (UC) and Crohn's disease (CD). Clinical features in both disorders include diarrhea, abdominal pain, weight loss, and increased risk of developing colorectal cancer \[[@b1-medscimonit-25-184]\]. The precise etiology of IBDs is not yet fully understood, but numerous studies have suggested that multiple factors, including heredity, environment, infection, and immunity, which interact each other, are involved in the development and exacerbation of the diseases \[[@b2-medscimonit-25-184]\]. With the wide application of genome-wide association studies (GWASs) and candidate gene association studies, many susceptibility *loci* for the predisposition of CD have been identified in the populations of northern European origin, such as *NOD2, ATG16L1,* and *IRGM* \[[@b3-medscimonit-25-184]--[@b8-medscimonit-25-184]\]. More than 30 single-nucleotide polymorphisms are definitively known to be associated with CD, although these *loci* account for only a minority of the genetic variance to CD in this population \[[@b9-medscimonit-25-184]\].

In humans, *Fucosyltransferase (FUT) 2* gene is located in the q13 region of chromosome 19 and encodes a specific fucosyltransferase enzyme. FUT2 enzyme can catalyze transfer of the sugar fucose to acceptor substrates and plays a vital role in the synthesis of histo-blood group antigens (HBGA), including ABH and Lewis (a) antigens \[[@b10-medscimonit-25-184]\]. In the past decade, an increasing number of studies has been conducted to explore the association between *FUT2* (*rs601338*) gene polymorphism and susceptibility to IBDs in different populations \[[@b11-medscimonit-25-184]--[@b18-medscimonit-25-184]\]. However, the role of genetic variations on *FUT2* gene (*rs601338*) in the progression of UC and CD remained unclear. These inconsistent results indicate the need for further analysis of the effect of *rs601338* polymorphism on UC and CD risks.

To date, no meta-analysis has been conducted to determine the correlation of *FUT2 gene (rs601338)* polymorphism with UC and CD risk. Thus, the aim of this study was to clarify the relationship between *FUT2 (rs601338)* gene variant with UC and CD risk by performing a meta-analysis.

Material and Methods
====================

Identification of eligible studies
----------------------------------

A comprehensive literature search was performed in the following databases: PubMed, EMBASE, CNKI, and Chinese Wangfang, up to 31 May 2018. The search terms and keywords were: "polymorphisms or variants", "fucosyltransferase 2 or FUT2", and "ulcerative colitis or Crohn's disease or inflammatory bowel disease". The research subjects were limited to humans, and the language was limited to English or Chinese. References from retrieved papers were also examined for additional studies.

Inclusion criteria
------------------

Studies were included in the meta-analysis if they met the following criteria: (1) study on the genetic relationship of *fucosyltransferase 2* gene (*rs601338*) with ulcerative colitis or Crohn's disease or inflammatory bowel disease; (2) case-control study design; (3) genotype distributions were available for both cases and controls to calculate an OR and its 95%CI. Exclusion criteria were as follows: (1) abstract, case report, editorial comment, and review; (2) repeated publication; (3) studies with insufficient genotypic data; (4) studies performed on animal models.

Quality score assessment
------------------------

The Newcastle-Ottawa scale was used to evaluate the quality of studies. The scale consists of 3 aspects: selection, comparability, and exposure, with a maximum score of 9 \[[@b19-medscimonit-25-184]\]. Any disagreements were adjudicated by a third reviewer. A total score of ≤3, 4--6, ≥7 was considered to indicate low-, medium-, and high-quality studies, respectively.

Data extraction
---------------

Two investigators independently and carefully extracted available data from each eligible study. The following details were extracted from all eligible studies: (1) first author's name, (2) year of study publication, (3) origin of participants, (4) race of included subjects, (5) source of control population, (6) sample size of cases and controls, and (7) results of the Hardy-Weinberg equilibrium (HWE) test for the controls. Discrepancies were resolved by discussion within our research team.

Statistical analysis
--------------------

The effect sizes were calculated using odds ratios (ORs) and 95% confidence interval (95%CI) to evaluate the association between the *fucosyltransferase 2 gene (rs601338)* polymorphism and inflammatory bowel disease, ulcerative colitis, and Crohn's disease risk. Pooled ORs were calculated by using 4 genetic models: allelic model (A *vs.* G), dominant model (AA+AG *vs.* GG), recessive model (AA *vs.* AG+GG), and homozygous model (AA *vs.* GG).

Heterogeneity among the eligible studies was analyzed by the chi-square test based on the Q statistic, with significant heterogeneity considered to be present at P value \<0.10 \[[@b20-medscimonit-25-184]\]. The I^2^ statistic test was used to quantify the heterogeneity across individual studies (P\<0.10 and I^2^ \>50% suggested heterogeneity). The fixed-effects model on the Mantel-Haenszel method was used to estimate the pooled OR if I^2^ \<50%; otherwise, the random-effects model on the DerSimonian and Laird method was used. Heterogeneity was also quantified by the I^2^ test, the values of I^2^ in 0--25%, 26--50%, and 50--100% were considered as lower, moderate, and high heterogeneity, respectively.

We evaluated the potential publication bias by using the Begg's funnel plot and the Egger's linear regression tests \[[@b21-medscimonit-25-184],[@b22-medscimonit-25-184]\], which measures funnel plot asymmetry on the natural logarithm scale of the effect size. One-way sensitivity analysis was used to assess which study has a significant impact on the stability of results.

All statistical analyses were performed using STATA version 11.0 software (STATA Corporation, College Station, TX). A 2-sided *P* value of less than 0.05 was considered statistically significant.

Results
=======

Characteristics of eligible studies
-----------------------------------

As [Figure 1](#f1-medscimonit-25-184){ref-type="fig"} shows, the selection process of the studies involved in this meta-analysis was performed according to PRISMA flow diagram. We found 44 potentially relevant papers from databases (16 in PubMed, 17 in Embase, 8 in CNKI, and 3 in Chinese Wangfang). Among these, 19 duplicates were removed, and another 14 studies were removed due to irrelevant topics, reviews, and not about IBDs or *fucosyltransferase 2* gene. The remaining 11 studies underwent full publication review, during which 3 studies were excluded due to insufficient data for calculating OR and 95%CI. Finally, a total of 8 studies were included in this meta-analysis. The basic characteristics of these studies are shown in [Table 1](#t1-medscimonit-25-184){ref-type="table"}.

*FUT 2* gene (*rs601338*) variant with IBDs
-------------------------------------------

The details of the association between *FUT 2* gene (*rs601338*) variant and risk of IBDs are shown in [Table 2](#t2-medscimonit-25-184){ref-type="table"}. The heterogeneity analysis of *rs601338* polymorphism showed significant heterogeneity in A *vs.* G (I^2^=79.6%, *P*\<0.001), AA+AG *vs.* GG (I^2^=82.5%, *P*\<0.001), AA *vs.* GG (I^2^=60.4%, *P*=0.014) genetic models in the all populations, so the random-effects model was used in these comparisons. Overall, significant associations between *FUT 2* gene (*rs601338*) polymorphism and risk for IBDs were found in the allelic model (A *vs.* G: OR=1.42, 95%CI=1.05\~1.91, *P*=0.022) and recessive model (AA *vs.* AG+GG: OR=1.29, 95%CI=1.10\~1.52, *P*=0.002) in all populations ([Figure 2](#f2-medscimonit-25-184){ref-type="fig"}). No significant associations were found in dominant and homozygous models in any populations.

Further subgroup analysis was carried out by grouping the data based on the population (7 studies in Chinese and 3 studies in whites). The results showed significant associations between *FUT2* gene (*rs601338*) polymorphism and risk for IBDs in allelic model (A *vs.* G: OR=2.35, 95%CI=1.66\~3.34, *P*\<0.001) and dominant model (AA+AG *vs.* GG: OR=2.53, 95%CI=1.76\~3.63, *P*\<0.001), but not in recessive and homozygous models in Chinese populations. We did not find any significant association between*FUT2* gene (*rs601338*) polymorphism and risk for IBD in all genetic models in whites.

*FUT2* gene (*rs601338*) variant with UC
----------------------------------------

The details of the association between *FUT2* gene (*rs601338*) variant and risk of UC are shown in [Table 3](#t3-medscimonit-25-184){ref-type="table"}. Overall, no significant association was found in any genetic models in any populations. However, when stratified by population, significant associations were found in the allelic model (A *vs.* G: OR=2.18, 95%CI=1.48\~3.23, *P*\<0.001) and dominant model (AA+AG *vs.* GG: OR=2.38, 95%CI=1.57\~3.62, *P*\<0.001), but not in recessive or homozygous models in Chinese populations ([Figure 3](#f3-medscimonit-25-184){ref-type="fig"}). Because there was only 1 study in a white population, it was excluded from subgroup analysis.

*FUT2* gene (*rs601338*) variant with CD
----------------------------------------

The detailed results of the association between *FUT2* gene (*rs601338*) variant and risk of CD are shown in [Table 3](#t3-medscimonit-25-184){ref-type="table"}. Overall, a significant association was found in the recessive model (AA *vs.* AG+GG: OR=1.55, 95%CI=1.25\~1.93,*P*\<0.001), but not in allelic, dominant, and homozygous models. Subgroup analysis showed that fucosyltransferase 2 gene (rs601338) variant was associated with CD risk in the allelic model (A *vs*. G: OR=3.26, 95%CI=1.50\~7.08, *P*=0.003) and dominant model (AA+AG *vs.* GG: OR=3.05, 95%CI=1.48\~6.29, *P*=0.003), but not in recessive and homozygous models in Chinese populations. We did not find any significant association between *FUT2* gene (*rs601338*) polymorphism and risk for CD in all genetic models in whites.

Sensitive analysis and publication bias
---------------------------------------

Sensitive analysis was conducted to determine if our results were substantially affected by any individual study. Our results suggested that the pooled effects were not significantly influenced by the omission of any individual study. Begg's and Egger's tests were performed in all comparisons except for comparisons of *FUT2* gene (*rs601338*) polymorphism and risk for CD in all genetic models in Chinese and white populations because only 2 studies were included in these comparisons. Begg's funnel plots showed the shape was symmetrical, and Egger's linear regression analysis indicated no publication bias ([Tables 2](#t2-medscimonit-25-184){ref-type="table"}, [3](#t3-medscimonit-25-184){ref-type="table"} and [Figure 4](#f4-medscimonit-25-184){ref-type="fig"}).

Discussion
==========

The associations between *FUT2* genes and susceptibility to IBDs in different populations have been widely reported. However, the outcomes of these studies vary from study to study. Hu et al. found that mutant A allele and AG genotype of *FUT2* gene (*rs601338*) were significantly increased in CD patients in Chinese populations \[[@b14-medscimonit-25-184]\], but they failed to find any association between *rs601338* of *FUT2* and UC severity \[[@b17-medscimonit-25-184]\]. Aheman et al. \[[@b12-medscimonit-25-184]\] observed that *rs601338* was statistically correlated with UC risk in Chinese populations, and AA homozygous frequencies of *rs601338* were lower in the UC groups than in the controls (12.2% *vs.* 15.2%). Parmar et al. \[[@b13-medscimonit-25-184]\] showed that the A allele of *rs601338* was associated with UC and UC+CD, indicating that FUT2 secretor status may play a role in IBD in the Finnish population. Wu et al. \[[@b18-medscimonit-25-184]\] showed that mutant A allele and genotype of FUT2 *rs601338* were significantly increased in CD patients from southeast China. However, there were no statistically significant differences in allele and genotype frequencies of FUT2 gene in UC patients compared to controls.

The inconsistency among different studies seems to be mainly due to the relatively small sample size of most studies and the different populations studied, and there was inadequate statistical power to detect a slight association between *FUT2* genes and susceptibility to IBDs. Other possible explanations include diverse study designs and methods, differences in race and geography, and publication bias. Meta-analysis is an effective statistical method that pools the results of independent studies to get comprehensive results. It has been widely used in evaluating the relationship between candidate genes and complex diseases with genetic predisposition.

This systematic review and meta-analysis was performed to determine the association between *rs601338* polymorphism and susceptibility to IBDs. The results demonstrated that *rs601338* polymorphism was associated with IBD in allelic and dominant genetic models in Chinese, but not in whites, in all genetic models. After being stratified by disease type, similar results were also presented in CD. In UC, this association was only observed in the Chinese population. The different results presented in different populations illustrates that *FUT2* genes polymorphisms with IBDs susceptibility might be associated with race. Of note, the results of*rs601338* polymorphism with CD risk in whites in this meta-analysis were inconsistent with the findings of the previous GWAS replication study (*rs601338* not covered in this GWAS, but covered in the replication study), which used a confirmatory cohort of 1174 cases and 357 controls and demonstrated that*FUT2 rs601338* is associated with CD in whites \[[@b11-medscimonit-25-184]\]. The cause of this inconsistency may be population differences (genetic and/or microbial), but it is also not unlikely that our study lacked power to identify an association of *FUT2* with CD. A larger follow-up study of CD in the white population will help elucidate the true effect of*FUT2* variation in CD risk.

Although the etiology and pathology of IBDs are unknown, a previous study showed that imbalances in the species of bacteria that live in our guts may be linked to the development of diseases \[[@b23-medscimonit-25-184]\]. FUT2 is the key enzyme determining the presentation of HBGA antigens in intestinal mucosal tissue \[[@b24-medscimonit-25-184]\]. HBGA, including ABH antigens and Lewis antigens, act not only as binding sites for intestinal microbes such as *Helicobacter pylori*, *Campylobacter jejuni*, norovirus, and rotavirus, but also are a carbon source for microbes, including *Escherichia coli* \[[@b25-medscimonit-25-184]--[@b27-medscimonit-25-184]\]. The FUT2 gene that codes for an alpha-(1,2)-fucosyltransferase is a Golgi stack membrane protein involved in creation of a precursor of the H antigen, which forms the basis of A and B antigen synthesis \[[@b28-medscimonit-25-184]\]. FUT3 encodes alpha-(1,3/4)-fucosyltransferase, which is required to synthesize Lewis a antigens, and mostly utilizes the H antigen, determined by FUT2, as a substrate to synthesize Lewis b antigen \[[@b29-medscimonit-25-184]\]. The intestinal microbiota can be influenced by FUT2 and FUT3, which control presentation of HBGA on the gastrointestinal mucosa and in bodily secretions \[[@b30-medscimonit-25-184]\]. FUT2 gene polymorphisms influence presentation of HBGA antigens in the gastrointestinal mucosa and their secretion, and further affect the microbiota composition in the human intestine \[[@b31-medscimonit-25-184]\].

Although an advantage of this meta-analysis is pooling good-quality individual studies with relatively large sample sizes for a comprehensive result, but several limitations should be addressed when interpreting our results. Firstly, we included relevant articles published only in English and Chinese, so language bias may exist in this study. Secondly, most of the studies are conducted in Chinese populations, and there were few studies in the white subgroup analyses, which could have led to insufficient statistic power to detect weak relationships. Thirdly, the onset of IBD is affected by risk factors such as age, sex, genetic variants, and exposure to environmental factors and their interactions. However, only gene polymorphisms were considered in this study. The effects of gene-gene and gene-environment interactions on the initiation and development of the disease need to be further studied.

Conclusions
===========

Our meta-analysis provides statistical evidence that the *FUT2* gene (rs601338) polymorphism is associated with IBD, UC, and CD in the Chinese population, but these results might not be generalizable to other ethnic populations. To provide better guidance for clinical practice, further well-designed studies are warranted to clarify the mechanism and increase comprehensive understanding of the role of the FUT2 gene (rs601338) polymorphism in IBDs.

**Source of support:** Departmental sources

**Conflicts of interest**

None.

![Selection of studies on the association between *FUT2* (*rs601338*) polymorphism and IBDs.](medscimonit-25-184-g001){#f1-medscimonit-25-184}

![Forest plot for pooled ORs for the associations between allelic (A *vs.* G) and dominant (AA+AG *vs.* GG) models of*rs601338* and IBDs risk in the Chinese population.](medscimonit-25-184-g002){#f2-medscimonit-25-184}

![Forest plot for pooled ORs for the associations between allelic (A *vs.* G) and dominant (AA+AG *vs.* GG) models of *rs601338* and UC risk in the Chinese population.](medscimonit-25-184-g003){#f3-medscimonit-25-184}

![(**A--D**) Begg's funnel plot for association between *rs601338* polymorphism and IBDs under 4 genetic models.](medscimonit-25-184-g004){#f4-medscimonit-25-184}

###### 

Basic characteristics of the eligibility studies included in this meta-analysis.

  First author \[ref\]                     Publication year   Region    Population   Sample size   Genotyping method   NOS Score   HWE                   
  ---------------------------------------- ------------------ --------- ------------ ------------- ------------------- ----------- ----------------- --- ---
  McGovern \[[@b11-medscimonit-25-184]\]   2010               USA       Caucasian    0             896                 3204        PCR               7   Y
  Aheman \[[@b12-medscimonit-25-184]\]     2012               China     Chinese      102           0                   310         PCR               7   Y
  Parmar \[[@b13-medscimonit-25-184]\]     2012               Finland   Caucasian    496           280                 2738        PCR               8   Y
  Hu \[[@b14-medscimonit-25-184]\]         2014               China     Chinese      0             273                 479         PCR               7   Y
  Xu \[[@b15-medscimonit-25-184]\]         2014               China     Chinese      233           0                   292         PCR               8   Y
  Lan \[[@b16-medscimonit-25-184]\]        2015               China     Chinese      160           0                   187         Direct sequence   7   Y
  Hu \[[@b17-medscimonit-25-184]\]         2016               China     Chinese      485           0                   580         PCR               8   Y
  Wu \[[@b18-medscimonit-25-184]\]         2017               China     Chinese      396           275                 502         PCR               8   Y

UC -- ulcerative colitis; CD -- Crohn's disease; PCR -- polymerase chain reaction; HWE -- Hardy-Weinberg disequilibrium; NOS -- Newcastle-Ottawa scale; USA --United States of America; Y -- indicate genotype distribution in control conform to HWE.

###### 

Meta-analysis of the association of fucosyltransferase 2 (rs601338) polymorphism with inflammatory bowel disease.

  Groups       Statistical model   Allele/ genotype   Method   I^2^ (%)   *P*^a^                  OR (95% CI)             *P*^b^        Begg's (*P*-value)   Egger's (*P*-value)
  ------------ ------------------- ------------------ -------- ---------- ----------------------- ----------------------- ------------- -------------------- ---------------------
  Overall      Allelic             A *vs.* G          Random   79.6       \<0.001                 **1.42 (1.05\~1.91)**   **0.022**     0.592                0.137
  Recessive    AA *vs.* AG+GG      Fixed              24.6     0.217      **1.29 (1.10\~1.52)**   **0.002**               0.858         0.849                
  Dominant     AA+AG *vs.* GG      Random             82.5     \<0.001    1.46 (1.00\~2.13)       0.053                   1.000         0.092                
  Homozygous   AA *vs.* GG         Random             60.4     0.014      1.30 (0.86\~1.97)       0.211                   0.536         0.664                
  Chinese      Allelic             A *vs.* G          Fixed    0.0        0.450                   **2.35 (1.66\~3.34)**   **\<0.001**   0.221                0.505
  Recessive    AA *vs.* AG+GG      Fixed              0.0      0.999      1.34 (0.62\~2.90)       0.462                   0.086         0.345                
  Dominant     AA+AG *vs.* GG      Fixed              0.0      0.472      **2.53 (1.76\~3.63)**   **\<0.001**             0.027         0.140                
  Homozygous   AA *vs.* GG         Fixed              0.0      0.998      1.68 (0.77\~3.63)       0.190                   1.000         0.347                
  Caucasian    Allelic             A *vs.* G          Random   90.4       \<0.001                 1.05 (0.96\~1.15)       0.665         1.000                0.707
  Recessive    AA *vs.* AG+GG      Random             83.1     0.003      1.29 (0.84\~1.98)       0.248                   1.000         0.758                
  Dominant     AA+AG *vs.* GG      Random             84.5     0.002      1.00 (0.70\~1.39)       0.936                   0.296         0.564                
  Homozygous   AA *vs.* GG         Random             88.1     \<0.001    1.23 (0.70\~2.15)       0.473                   1.000         0.633                

R -- odds ratio; CI -- confidence interval; *P*^a^ -- *P* value for between-study heterogeneity; *P*^b^ -- *P* value for test of the association.

###### 

Meta-analysis of the association of fucosyltransferase 2 (rs601338) polymorphism with ulcerative colitis and Crohn's disease.

  Groups       Statistical model   Allele/ genotype   Method   I^2^ (%)   *P*^a^                  OR (95% CI)             *P*^b^        Begg's (*P*-value)   Egger's (*P*-value)
  ------------ ------------------- ------------------ -------- ---------- ----------------------- ----------------------- ------------- -------------------- ---------------------
  **UC**                                                                                                                                                     
  Overall      Allelic             A *vs.* G          Random   82.2       0.001                   1.37 (0.68\~2.75)       0.378         1.000                0.414
  Recessive    AA *vs.* AG+GG      Fixed              0.0      0.951      1.00 (0.78\~1.30)       0.984                   0.734         0.242                
  Dominant     AA+AG *vs.* GG      Random             86.4     \<0.001    1.44 (0.61\~3.45)       0.407                   1.000         0.397                
  Homozygous   AA *vs.* GG         Fixed              0.0      0.562      0.94 (0.71\~1.23)       0.645                   0.734         0.363                
  Chinese      Allelic             A *vs.* G          Fixed    16.9       0.307                   **2.18 (1.48\~3.23)**   **\<0.001**   0.296                0.110
  Recessive    AA *vs.* AG+GG      Fixed              0.0      0.999      1.27(0.55\~2.94)        0.572                   1.000         0.428                
  Dominant     AA+AG *vs.* GG      Fixed              22.3     0.273      **2.38 (1.57\~3.62)**   **\<0.001**             0.296         0.037                
  Homozygous   AA *vs.* GG         Fixed              0.0      0.951      1.65 (0.72\~3.82)       0.240                   1.000         0.055                
  **CD**                                                                                                                                                     
  Overall      Allelic             A *vs.* G          Random   84.0       \<0.001                 1.47(0.96\~2.26)        0.078         0.734                0.447
  Recessive    AA *vs.* AG+GG      Fixed              49.1     0.117      **1.55 (1.25\~1.93)**   **\<0.001**             0.734         0.980                
  Dominant     AA+AG *vs.* GG      Random             81.3     0.001      1.49 (0.89\~2.50)       0.130                   1.000         0.308                
  Homozygous   AA *vs.* GG         Random             68.5     0.023      1.50 (0.79\~2.85)       0.216                   0.734         0.952                
  Chinese      Allelic             A *vs.* G          Fixed    0.0        0.960                   **3.26 (1.50\~7.08)**   **0.003**     --                   --
  Recessive    AA *vs.* AG+GG      Fixed              0.0      0.984      1.79 (0.25\~12.74)      0.561                   --            --                   
  Dominant     AA+AG *vs.* GG      Fixed              0.0      0.957      **3.05 (1.48\~6.29)**   **0.003**               --            --                   
  Homozygous   AA *vs.* GG         Fixed              0.0      0.984      1.83 (0.26\~13.04)      0.546                   --            --                   
  Caucasian    Allelic             A *vs.* G          Random   91.9       \<0.001                 1.17 (0.76\~1.81)       0.477         --                   --
  Recessive    AA *vs.* AG+GG      Random             83.0     0.015      1.49 (0.86\~2.59)       0.158                   --            --                   
  Dominant     AA+AG *vs.* GG      Random             88.4     0.003      1.09 (0.65\~1.84)       0.749                   --            --                   
  Homozygous   AA *vs.* GG         Random             89.4     0.002      1.47 (0.68\~3.19)       0.332                   --            --                   

R -- odds ratio; CI -- confidence interval. *P*^a^ -- *P* value for between-study heterogeneity; *P*^b^ -- *P* value for test of the association between *rs601338* polymorphism with ulcerative colitis and Crohn's disease.
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